News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer


9/25/2007 9:34:18 AM

VIENNA, Austria, September 25 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced the appointment of Dr. Geert Mudde as Chief Scientific Officer. Dr. Mudde has over 20 years of experience in the biotech and pharmaceutical industry, specializing in preclinical research and development. He comes to f-star from Baxter BioScience, where he was Director of Discovery Research and Technical Assessment.

"Geert brings in a wealth of knowledge and experience in industrial research and development which will be of prime importance in shaping f-star's proprietary product development programs. We are delighted that he joins the executive management team at such a decisive stage of the Company's development," said Dr. Gottfried Himmler, CEO f-star.

"f-star has now established its proprietary Modular Antibody Technology as a unique antibody engineering technology with an excellent IP position. Based on the recent financing the Company is now prepared to move to the next stage and define its own development programs," said Dr. Geert Mudde, CSO. "I am excited to contribute to this important development step as part of the executive team," he added.

Dr. Mudde was one of the founders of f-star in 2006 and worked as a consultant to the Company since then. Prior to his most recent position at Baxter BioScience he held senior-level positions in the international biotechnology and pharmaceutical industry, including VP Research at Igeneon, Austria, Director Immunology at Ingenium Pharmaceuticals, Germany, and Director of Allergy & Inflammation/Immunology at Parke Davis in Paris, France. Before that he worked at Sandoz/Novartis and at the Swiss Institute for Allergy Research. Dr. Mudde received his PhD in immunology from the University Utrecht (The Netherlands).

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAbsquared) can be created.

The Company was founded by a team of experienced antibody engineering and biotech executives. Seed-financed by Austrian government agencies and Atlas Venture in 2006, the Company recently closed a Series A financing round co-led by Aescap Venture and Atlas Venture and has raised EUR 10.0m so far. f-star has 15 employees at its research site in Vienna, Austria.

For more information, visit http://www.f-star.com Company contact: Dr. Eugen Stermetz CFO f-star Biotechnologische Forschungs- und Entwicklungs-GmbH +43-1-230-60-30-45 Muthgasse 18 A-1190 Vienna, Austria http://www.f-star.com Media contact: Frank Butschbacher Investor Relations & Communications +43-650-78-44-940 office@butschbacher.nethttp://www.butschbacher.net

f-star

CONTACT: Company contact: Dr. Eugen Stermetz, CFO, f-starBiotechnologische Forschungs- und Entwicklungs-GmbH, +43-1-230-60-30-45,Muthgasse 18, A-1190 Vienna, Austria; Media contact:, Frank Butschbacher,Investor Relations & Communications, +43-650-78-44-940,office@butschbacher.net


Read at BioSpace.com


comments powered by Disqus
f-Star
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES